FINANCIAL SUPERVISION AUTHORITY

Current report No 2/2018

Date prepared: 05/01/2018

Abbreviated name of the issuer:
MABION S.A.

Subject

Positive initial results of the MabionCD20 NHL clinical trial in terms of pharmacokinetic secondary endpoints.

Legal basis

Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information.

Content of the report:

Board of Mabion S.A. (The "Company", "Issuer") hereby informs that on 5 January 2018 an external contractor provided it with information about the initial results of the clinical trial analysis regarding MabionCD20 used to treat patients with non-Hodgkin Lymphoma (NHL) in terms of two primary pharmacokinetic endpoints of the clinical trial. Initial results indicate that the assumed equivalence criteria have been met.

In the coming weeks, independent contractors are also expected to provide Mabion with preliminary findings of the trial on other endpoints and characteristics of adverse effects.

The final version of reports from the trial will be used in the marketing authorisation application (MAA) which the company plans to submit to the European Medicines Agency (EMA). “Positive preliminary results of the comparative analysis do not guarantee that the final results will be positive. Furthermore, positive results of the trial do not guarantee that the Product will be approved by the European Medicines Agency.